Navigation Links
Alfacell's ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment
Date:4/14/2008

en, Alfacell's chief executive officer, added: "This work by Dr. Lee and his team provides further evidence of the potential for ONCONASE to mitigate the resistance that often develops in, and confounds the treatment of NSCLC."

About ONCONASE(R)

ONCONASE is a first-in-class product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit http://www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potent
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
2. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
3. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
4. Pre-Clinical Data Show Intracellular Pathways Affected by ONCONASE(R)
5. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
6. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
7. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
8. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
11. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... BOULDER, Colo. , April 27, 2015 ... will report financial results for the third ... conference call to discuss those results on ... Executive Officer will lead the call.Date:Monday, May ... Code: 5249676 Webcast, including Replay and Conference ...
(Date:4/27/2015)... Inc. (NYSE: CRY ), a leading medical device ... surgery, announced today that it has received a close-out ... ("FDA") verifying that the Company has successfully implemented corrective ... received from the FDA in January 2013. ... by the FDA at CryoLife,s manufacturing facility and headquarters ...
(Date:4/27/2015)... NEW YORK , April 27, 2015   ... management solutions, will showcase advances in monitored care that ... the upcoming ATA 2015 Conference, May 2-5 ... Center. AMC Health will share information about ... monitored care to help transform and personalize healthcare delivery ...
Breaking Medicine Technology:CryoLife Announces Resolution of FDA Warning Letter 2AMC Health to Showcase Advances in Monitored Care at ATA 2015 2AMC Health to Showcase Advances in Monitored Care at ATA 2015 3AMC Health to Showcase Advances in Monitored Care at ATA 2015 4
... DIEGO, Oct. 13 RESMED INC. (NYSE: RMD ... will release its results for the first quarter of fiscal ... ResMed,s results will be issued after 1:00 p.m. Pacific Time ... to review its results, market trends, and future outlook. ...
... Care Continuum Alliance honored Kaiser Permanente,s ALL/PHASE initiative ... on Health" at The Forum 10 conference ... low-cost and generic medications and clinical interventions to reduce ... communities, including those served by safety net organizations. ...
Cached Medicine Technology:ResMed Announces Conference Call and Webcast to Discuss First Quarter 2011 Results 2Kaiser Permanente's ALL/PHASE Initiative Wins 2010 Care Continuum Alliance Quality Impact Award for Greatest Impact on Health 2Kaiser Permanente's ALL/PHASE Initiative Wins 2010 Care Continuum Alliance Quality Impact Award for Greatest Impact on Health 3
(Date:4/28/2015)... Henderson, NV (PRWEB) April 28, 2015 ... University's Center for Ethics (June 27, 2014), prescription ... the world. Medical Science is becoming increasingly aware of ... on the market, such as chemotherapy drugs to treat ... bacteria that are quickly evolving to become increasingly resistant ...
(Date:4/28/2015)... 2015 Foot and Ankle Specialists ... D. Palmer ( Annapolis and Clarksville Divisions ) ... at the Maryland Podiatric Medical Association meeting on April ... University in 1992 with a Bachelor of Arts in ... in intercollegiate soccer, track and cross-country. He then attended ...
(Date:4/27/2015)... 2015 Churchview Supportive Living, a Gardant ... Brunch and Fashion Show from 10:30 a.m. to noon ... at 2626 W. 63rd St. in Chicago, serves low-income ... help to maintain their independence. , “Mothers, grandmothers, godmothers ... Mother’s Day Brunch,” said Director of Marketing Elizabeth Clippard. ...
(Date:4/27/2015)... April 28, 2015 Healthcare marketing ... paper called “Website Anatomy 101.” Available ... the necessary design elements for a successful hospital ... responsive design, user experience, search results and lead ... of a well-designed website on patient volume and ...
(Date:4/27/2015)... A variety of events are planned to support ... abuse. Programming for Jericho for boys is being enhanced this ... summer. , The first event is a sellout golf tournament ... Youth Town Jim Jackson Golf Classic will be held at ... tee times at 8 a.m. and 1 p.m. Team sponsorships ...
Breaking Medicine News(10 mins):Health News:Trivedi Science™ Announces the Beginning of Their Science Research to Create Highly Effective Pharmaceutical Drugs with Minimal Side Effects 2Health News:Trivedi Science™ Announces the Beginning of Their Science Research to Create Highly Effective Pharmaceutical Drugs with Minimal Side Effects 3Health News:Trivedi Science™ Announces the Beginning of Their Science Research to Create Highly Effective Pharmaceutical Drugs with Minimal Side Effects 4Health News:Foot and Ankle Specialists of the Mid-Atlantic, LLC Podiatrist Receives Maryland Podiatric Medical Association Outstanding Service Award 2Health News:Churchview Supportive Living Community in Chicago to Host Mother's Day Brunch 2Health News:Smith & Jones Publishes 2015 Website Design White Paper 2Health News:Golf, Sermon on the Mount and More to Support Youth Town’s Jericho and Eden Programs 2
... Feb. 20 LifeSync Corporation is,pleased to announce ... Vice,President of Research and Development. Dr. Phelps, who ... be responsible for leading all,product design and development ... the Georgia Electronic Design Center (GEDC),at the Georgia ...
... Holmes,today announced that, due to continuing declines in Portamedic ... the fourth quarter 2007,excluding the gain on sale of ... part to a greater than expected,reduction in paramedical exams ... prior year. Regarding 2008, the Company no longer expects ...
... dermal filler market is expected to grow at a compound ... to Millennium Research Group, WALTHAM, Mass., Feb. 20 ... Aesthetic,Orthopedic, and Emerging Applications 2008 report, the US hyaluronic acid,(HA) ... rate of,nearly 20% from 2006 through 2011., Growth in ...
... YUCAIPA, Calif., Feb. 20 Ingen Technologies,Inc. ... manufacturer, announced,today that the Taiwan registration process ... International Holding Company,Ltd., has been initiated. Progressive ... Taipei Economic and Cultural Representative,Office in the ...
... Erbitux Will Earn Gold-Standard Status in 2011, ... to a New Report from Decision Resources, WALTHAM, ... leading research and advisory firms focusing on pharmaceutical and,healthcare ... is the,attribute that most influences oncologists, prescribing decisions in ...
... -- China Dongsheng,International, Inc. (OTC Bulletin Board: CDSG), ... personal care products provider,in China, today announced the ... quarter ended December 31, 2007., -- ... its own branded products ...
Cached Medicine News:Health News:LifeSync Hires Dr. Mark Phelps to Lead Research & Development 2Health News:Hooper Holmes Updates Guidance 2Health News:Hooper Holmes Updates Guidance 3Health News:Hyaluronic Acid Dermal Filler Market Skyrockets 2Health News:-Ingen Technologies Registers Oxyview(R) in Taiwan- 2Health News:-Ingen Technologies Registers Oxyview(R) in Taiwan- 3Health News:In Combination With FOLFOX4, the Effect of Erbitux and Avastin On Survival Rates Will Drive Prescription Decisions in the Treatment of Stage III Colon Cancer 2Health News:China Dongsheng International Announces Fiscal Year 2008 Second Quarter Financial Results 2Health News:China Dongsheng International Announces Fiscal Year 2008 Second Quarter Financial Results 3Health News:China Dongsheng International Announces Fiscal Year 2008 Second Quarter Financial Results 4Health News:China Dongsheng International Announces Fiscal Year 2008 Second Quarter Financial Results 5Health News:China Dongsheng International Announces Fiscal Year 2008 Second Quarter Financial Results 6
The ring maintains the bag tension avoiding the development of posterior capsule pleats. It is also established to compensate the efforts induced during the bag retraction....
... Type 14, 14A and 14C have been approved. ... to accommodate the variations in the size of ... tension rings are designed to stabilize the capsule ... large panel of U.S. ophthalmologists. For implatations ...
... is a device designed for permanent implantation ... removal surgery. It provides secondary capsular bag ... The CTR is a uniplanar, 270-degree, semi-circle ... absorbing polymethylmethacrylate (PMMA) with one manipulation eyelet ...
Stainless steel cartilage scissors....
Medicine Products: